MX2010001976A - Uso de urato oxidasa para el tratamiento o profilaxis de trastornos o secuelas indirectas del corazon causadas por sucesos isquemicos o de reperfusion. - Google Patents
Uso de urato oxidasa para el tratamiento o profilaxis de trastornos o secuelas indirectas del corazon causadas por sucesos isquemicos o de reperfusion.Info
- Publication number
- MX2010001976A MX2010001976A MX2010001976A MX2010001976A MX2010001976A MX 2010001976 A MX2010001976 A MX 2010001976A MX 2010001976 A MX2010001976 A MX 2010001976A MX 2010001976 A MX2010001976 A MX 2010001976A MX 2010001976 A MX2010001976 A MX 2010001976A
- Authority
- MX
- Mexico
- Prior art keywords
- prophylaxis
- treatment
- urate oxidase
- ischemic
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
La invención se refiere al uso de una urato oxidasa, de preferencia urato oxidasa recombinante, por ejemplo rasburicasa, para producir un medicamento para el tratamiento o profilaxis de trastornos o secuelas indirectas del corazón causados por sucesos isquémicos o de reperfusión, por ejemplo durante y después de cirugía cardiaca tal como CABG (bypass coronario arterial por injerto), PCI (intervención coronaria percutánea), trasplantes, post-infarto de miocardio y para el tratamiento o profilaxis de enfermedad arterial coronaria o fallo cardiaco, por ejemplo fallo cardiaco congestivo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07291072 | 2007-09-05 | ||
US1524007P | 2007-12-20 | 2007-12-20 | |
PCT/EP2008/006858 WO2009030373A1 (en) | 2007-09-05 | 2008-08-20 | Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010001976A true MX2010001976A (es) | 2010-03-10 |
Family
ID=38713162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010001976A MX2010001976A (es) | 2007-09-05 | 2008-08-20 | Uso de urato oxidasa para el tratamiento o profilaxis de trastornos o secuelas indirectas del corazon causadas por sucesos isquemicos o de reperfusion. |
Country Status (22)
Country | Link |
---|---|
US (1) | US20100266567A1 (es) |
EP (1) | EP2197550A1 (es) |
JP (1) | JP2011509920A (es) |
KR (1) | KR20100053609A (es) |
CN (1) | CN101801460A (es) |
AR (1) | AR068360A1 (es) |
AU (1) | AU2008295145B2 (es) |
BR (1) | BRPI0816406A2 (es) |
CA (1) | CA2697929A1 (es) |
CL (1) | CL2008002623A1 (es) |
CO (1) | CO6260090A2 (es) |
IL (1) | IL204259A (es) |
MA (1) | MA31624B1 (es) |
MX (1) | MX2010001976A (es) |
MY (1) | MY183770A (es) |
NZ (1) | NZ583635A (es) |
PA (1) | PA8794801A1 (es) |
PE (1) | PE20090642A1 (es) |
TW (1) | TW200927929A (es) |
UY (1) | UY31320A1 (es) |
WO (1) | WO2009030373A1 (es) |
ZA (1) | ZA201000774B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5114972A (en) * | 1990-07-30 | 1992-05-19 | Tsuyoshi Ohnishi | Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities |
CA2413201A1 (en) * | 2000-06-28 | 2002-01-03 | Merck & Co., Inc. | Treatment for cardiovascular disease |
AU2003275160A1 (en) * | 2002-09-20 | 2004-04-08 | Oregon Health And Science University | Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries |
MXPA06009072A (es) * | 2004-02-09 | 2007-03-29 | Human Genome Sciences Inc | Proteinas de fusion de albumina. |
WO2005099758A2 (en) * | 2004-04-17 | 2005-10-27 | The Board Of Trustees The Leland Standford Junior University | Injectable bioartificial tissue matrix |
US20070197512A1 (en) * | 2006-01-27 | 2007-08-23 | Japan Tobacco Inc. | Carboxylic Acid Compounds and Use Thereof |
-
2008
- 2008-08-20 WO PCT/EP2008/006858 patent/WO2009030373A1/en active Application Filing
- 2008-08-20 KR KR1020107004878A patent/KR20100053609A/ko not_active Application Discontinuation
- 2008-08-20 NZ NZ583635A patent/NZ583635A/en not_active IP Right Cessation
- 2008-08-20 MY MYPI2010000585A patent/MY183770A/en unknown
- 2008-08-20 JP JP2010523299A patent/JP2011509920A/ja active Pending
- 2008-08-20 MX MX2010001976A patent/MX2010001976A/es active IP Right Grant
- 2008-08-20 AU AU2008295145A patent/AU2008295145B2/en not_active Ceased
- 2008-08-20 BR BRPI0816406A patent/BRPI0816406A2/pt not_active IP Right Cessation
- 2008-08-20 CN CN200880105379A patent/CN101801460A/zh active Pending
- 2008-08-20 EP EP08785655A patent/EP2197550A1/en not_active Withdrawn
- 2008-08-20 CA CA2697929A patent/CA2697929A1/en not_active Abandoned
- 2008-09-03 AR ARP080103828A patent/AR068360A1/es not_active Application Discontinuation
- 2008-09-03 PE PE2008001545A patent/PE20090642A1/es not_active Application Discontinuation
- 2008-09-03 UY UY31320A patent/UY31320A1/es not_active Application Discontinuation
- 2008-09-03 PA PA20088794801A patent/PA8794801A1/es unknown
- 2008-09-03 TW TW097133674A patent/TW200927929A/zh unknown
- 2008-09-04 CL CL2008002623A patent/CL2008002623A1/es unknown
-
2010
- 2010-02-02 ZA ZA2010/00774A patent/ZA201000774B/en unknown
- 2010-02-22 MA MA32638A patent/MA31624B1/fr unknown
- 2010-02-24 CO CO10021841A patent/CO6260090A2/es not_active Application Discontinuation
- 2010-03-01 US US12/715,061 patent/US20100266567A1/en not_active Abandoned
- 2010-03-02 IL IL204259A patent/IL204259A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PE20090642A1 (es) | 2009-06-18 |
CL2008002623A1 (es) | 2009-01-16 |
UY31320A1 (es) | 2009-04-30 |
NZ583635A (en) | 2011-06-30 |
CA2697929A1 (en) | 2009-03-12 |
ZA201000774B (en) | 2011-04-28 |
PA8794801A1 (es) | 2009-04-23 |
CN101801460A (zh) | 2010-08-11 |
AR068360A1 (es) | 2009-11-11 |
AU2008295145A1 (en) | 2009-03-12 |
WO2009030373A1 (en) | 2009-03-12 |
AU2008295145B2 (en) | 2013-12-05 |
RU2010112867A (ru) | 2011-10-10 |
MY183770A (en) | 2021-03-12 |
US20100266567A1 (en) | 2010-10-21 |
JP2011509920A (ja) | 2011-03-31 |
IL204259A (en) | 2013-06-27 |
CO6260090A2 (es) | 2011-03-22 |
TW200927929A (en) | 2009-07-01 |
EP2197550A1 (en) | 2010-06-23 |
MA31624B1 (fr) | 2010-08-02 |
KR20100053609A (ko) | 2010-05-20 |
BRPI0816406A2 (pt) | 2017-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2024202464A1 (en) | Pyrimidinedione compounds against cardiac conditions | |
NZ600400A (en) | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | |
TW200616996A (en) | Compounds, compositions and methods | |
EP3026044B8 (en) | Prolyl hydroxylase inhibitors and methods of use | |
NO20072223L (no) | Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse | |
NO20072160L (no) | Hydroksybenzoatsalter av metanikotinforbindelser | |
WO2011057249A3 (en) | Treatment of heart disease | |
WO2007078839A3 (en) | Compounds, compositions and methods | |
NO20075400L (no) | Fremgangsmater, sammensetninger og formuleringer for a forebygge eller lindre ugunstige virkninger i en pasient | |
WO2011057251A3 (en) | Treatment of heart disease | |
Settleman | Tension precedes commitment—even for a stem cell | |
MX2012001829A (es) | Compuestos de azetidinona y uso medico de los mismos. | |
IL204259A (en) | Use of resburicase to prepare a drug to treat or prevent heart disease or heart problems caused by previous events or blockage of blood flow to the heart | |
MX2008009161A (es) | Tratamiento de enfermedad cardiovascular en mexicano-americanos, usando nebivolol. | |
TH104398B (th) | การใช้ยูเรตออกซิเดสเพื่อการรักษาหรือการป้องกันความผิดปกติหรือผลกระทบทางอ้อมที่ตามมาของหัวใจที่เกิดจากภาวะพร่องเลือดหรือผ่านเลือด | |
JP2011509920A5 (es) | ||
WO2007019302A8 (en) | Treatment of cardiac hypertrophy by activation of ciliary neurtrophic factor receptor | |
TW200806296A (en) | Method and compositions for the treatment of vascular disease | |
Morecroft et al. | Combined Serotonin Transporter and 5-HT1B Receptor Inhibitor LY393558 Reverses Established Pulmonary Hypertension (PAH) in Mice. | |
MA38789B1 (fr) | Composés de pyrimidine-dione contre les affections cardiaques | |
UA107447C2 (uk) | Спосіб оцінки ефективності лікування пропранололом хворих на ішемічну хворобу серця з стенокардією та артеріальною гіпертензією з порушенням діастолічної функції лівого шлуночка по "гіпертрофічному" типу |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |